Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maplirpacept + PLD in Platinum-Resistant Ovarian Cancer
NCT05261490Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Aug 2022
- Primary completion
- Oct 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of maplirpacept in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC) (2 arms), sponsored by Pfizer. Primary endpoint: Number of Participants With Dose Limiting Toxicities. Started Aug 2022; status: terminated.
02
Drugs
maplirpacept
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT05261490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05261490.